Dr. Alexander Z. Wei, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 9
- In the NPI registry since
- 2017
- Medicare patients seen, 2024
- 172
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2017Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
NY license 303021 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- New York-Presbyterian Hospital New York, NY
Medical groups
- Trustees of Columbia University in The City of New York (2,296 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 172
- Services billed
- 1,209
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 193 | 83 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 61 | 26 |
| Established patient office or other outpatient visit, 30-39 minutes | 46 | 27 |
| New patient office or other outpatient visit, 60-74 minutes | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Amlodipine Besylate Other prescribers in New York, NY | 22 |
| Metoprolol Succinate Other prescribers in New York, NY | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 15 payments worth $7,971 in total to this clinician.
| Merck Sharp & Dohme LLC | $7,149 |
|---|---|
| Telix Pharmaceuticals | $604 |
| AstraZeneca Pharmaceuticals LP | $137 |
| E.r. Squibb & Sons, L.l.c. | $80.76 |
| Compensation for services other than consulting (speaking, faculty) | $5,760 |
|---|---|
| Travel and Lodging | $1,402 |
| Food and Beverage | $809 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Jun 23, 2025 | Compensation for services other than consulting (speaking, faculty) KEYTRUDA · ONCOLOGY | $5,760 |
| Merck Sharp & Dohme LLC Jun 12, 2025 | Travel and Lodging KEYTRUDA · ONCOLOGY · travel to Sun Prairie, WI · in-kind | $578 |
| Merck Sharp & Dohme LLC Jun 12, 2025 | Travel and Lodging KEYTRUDA · ONCOLOGY · travel to Sun Prairie, WI · in-kind | $336 |
| Merck Sharp & Dohme LLC Jun 12, 2025 | Travel and Lodging KEYTRUDA · ONCOLOGY · travel to Sun Prairie, WI · in-kind | $197 |
| Merck Sharp & Dohme LLC Jun 23, 2025 | Travel and Lodging KEYTRUDA · ONCOLOGY · travel to Sun Prairie, WI | $150 |
| Telix Pharmaceuticals Dec 13, 2025 | Travel and Lodging ILLUCCIX · PROSTATE CANCER DIAGNOSIS · travel to NEW YORK, NY | $141 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 6 companies. The companies reported $443,411 in research payments for these studies, mostly to the institutions running them.
- A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Eli Lilly and Company · Recruiting · NCT06465069 - A Phase I/II, Multi-center, Open Label Study of DYP688 in Patients With Metastatic Uveal Melanoma (MUM) and Other GNAQ/11 Mutant Melanomas
Novartis Pharmaceuticals Corporation - FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Eli Lilly and Company · Recruiting · NCT05614739 - Phase 1/2a First-In-Human Study of BMS-986207 Monoclonal Antibody Alone and in Combination with Nivolumab or with Nivolumab and Ipilimumab in Advanced Solid Tumors
E.r. Squibb & Sons, L.l.c. - IMCODE004
Genentech, Inc. - A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for…
AstraZeneca UK Limited - Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers
Regeneron Pharmaceuticals, Inc. · Completed · NCT03005782
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.